Phase III trial shows lorlatinib highly effective against ALK-positive non–small cell lung cancer

A large team of medical researchers and doctors has found via phase III clinical trial that the ALK inhibitor lorlatinib is highly effective for treating non–small cell lung cancer (NSCLC).

​Medical Xpress – latest medical and health news stories

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *